
Archive
Hot Topics of the Day are picked by experts to capture the latest information and publications on public health genomics and precision health for various diseases and health topics. Sources include published scientific literature, reviews, blogs and popular press articles.
Sign up MyPHGKB to receive the daily hot topic email alert.
Archived Hot Topics of the Day By Date
Germline Sequencing Analysis to Inform Clinical Gene Panel Testing for Aggressive Prostate Cancer.
Burcu F Darst et al. JAMA Oncol 2023 9
(Posted: Sep-22-2023 2PM)
Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant Prostate Cancer.
Clara Hwang et al. JAMA Netw Open 2023 9 (9) e2334208
(Posted: Sep-21-2023 2PM)
An international multi-institutional validation study of the algorithm for prostate cancer detection and Gleason grading
Y Tolkach et al, NPJ Precision Oncology, August 15, 2023
(Posted: Aug-16-2023 8AM)
BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype
H Fettle et al, ebiomedicine, August 5, 2023
(Posted: Aug-07-2023 9AM)
Meeting the need for germline testing
Lancet Oncology editorial, July 2023
(Posted: Jul-05-2023 7AM)
Precision medicine meets cancer vaccines.
et al. Nat Med 2023 6
(Posted: Jun-22-2023 7AM)
Evaluating approaches for constructing polygenic risk scores for prostate cancer in men of African and European ancestry.
Burcu F Darst et al. Am J Hum Genet 2023 6
(Posted: Jun-15-2023 8AM)
Genetically adjusted PSA levels for prostate cancer screening.
Linda Kachuri et al. Nat Med 2023 6
(Posted: Jun-02-2023 6AM)
Clinical utility of polygenic risk scores: a critical 2023 appraisal
S Koch et al, J Comm Genetics, May 3, 2023
(Posted: May-03-2023 7AM)
Predicting response to enzalutamide and abiraterone in metastatic prostate cancer using whole-omics machine learning.
Anouk C de Jong et al. Nature communications 2023 4 (1) 1968
(Posted: Apr-10-2023 7AM)
A Polygenic Risk Score for Prostate Cancer Risk Prediction.
Kerry R Schaffer et al. JAMA internal medicine 2023 3
(Posted: Mar-07-2023 6PM)
Bringing Prostate Cancer Polygenic Risk Scores to the Clinic.
Robert J Klein et al. JAMA internal medicine 2023 3
(Posted: Mar-07-2023 6PM)
Association between genetically proxied PCSK9 inhibition and prostate cancer risk: A Mendelian randomisation study.
Fang Si et al. PLoS medicine 2023 1 (1) e1003988
(Posted: Jan-04-2023 6AM)
Genetic determinants for the racial disparities in the risk of prostate and testicular cancers
I Uzamere et al, Comm Med, November 2, 2022
(Posted: Nov-02-2022 6AM)
Polygenic risk of any, metastatic, and fatal prostate cancer in the Million Veteran Program.
Pagadala Meghana S et al. Journal of the National Cancer Institute 2022 10
(Posted: Oct-29-2022 10AM)
Two Factors to ID Men at Highest Risk for Prostate Cancer Death
R Nelson, Medscape, September 2022
(Posted: Oct-03-2022 7AM)
The potential of polygenic risk scores for prostate cancer
Genomics education program blog, September 30, 2022
(Posted: Oct-02-2022 9AM)
How to improve the diagnosis of prostate cancer
B Plackett, Nature, September 2022
(Posted: Sep-18-2022 4AM)
Accumulation of copy number alterations and clinical progression across advanced prostate cancer
A Grist et al, Genome Medicine, September 5, 2022
(Posted: Sep-06-2022 7AM)
Genomic testing in localized prostate cancer can identify subsets of African-Americans with aggressive disease.
Awasthi Shivanshu et al. Journal of the National Cancer Institute 2022 9
(Posted: Sep-04-2022 9AM)
Developing machine learning algorithms for dynamic estimation of progression during active surveillance for prostate cancer.
Lee Changhee et al. NPJ digital medicine 2022 8 (1) 110
(Posted: Aug-08-2022 10AM)
Insight into how patients with prostate cancer interpret and communicate genetic test results: implications for families.
Leader Amy E et al. Journal of community genetics 2022 7
(Posted: Jul-28-2022 6AM)
An appraisal of genetic testing for prostate cancer susceptibility
A Finch et al, NPJ Precision Oncology, June 22, 2022
(Posted: Jun-22-2022 10AM)
Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials
A Esteva et al, NPJ Digital Medicine, June 8, 2022
(Posted: Jun-08-2022 6AM)
Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer
RP Graf et al, JAMA Network Open, March 31, 2022
(Posted: Apr-01-2022 8AM)
Care of men with cancer-predisposing BRCA variants
R Horton et al, BMJ, October 14,2021
(Posted: Oct-15-2021 6AM)
Adoption of New Risk Stratification Technologies Within US Hospital Referral Regions and Association With Prostate Cancer Management
MS Leapman et al, JAMA Network Open, October 8, 2021
(Posted: Oct-11-2021 11AM)
How I faced my prostate cancer: a molecular biologist’s perspective
M Zuradelli, NPJ Precision Oncology, September 2021
(Posted: Sep-28-2021 6AM)
Uptake and acceptability of a mainstreaming model of hereditary cancer multigene panel testing among patients with ovarian, pancreatic, and prostate cancer
JG Hamilton et al, Genetics in Medicine, July 13, 2021
(Posted: Jul-14-2021 7AM)
Yet Another Automated Gleason Grading System (YAAGGS) by weakly supervised deep learning
Y Munn et al, NPJ Digital Medicine, June 14, 2021
(Posted: Jun-14-2021 6AM)
Urinary exosome microRNA signatures as a noninvasive prognostic biomarker for prostate cancer
S Shin et al, NPJ Digital Medicine, June 11, 2021
(Posted: Jun-12-2021 7AM)
Intrinsic Biologic Differences Unlikely to Be Driving Prostate Cancer Disparities
ASCO Daily News, June 8, 2021
(Posted: Jun-09-2021 7AM)
Concordance of DNA Repair Gene Mutations in Paired Primary Prostate Cancer Samples and Metastatic Tissue or Cell-Free DNA.
Schweizer Michael T et al. JAMA oncology 2021 6
(Posted: Jun-09-2021 7AM)
Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial.
Feng Felix Y et al. JAMA oncology 2021 Feb
(Posted: Feb-12-2021 0PM)
Deciphering Genomic Risk in Prostate Cancer-Ready for Prime Time.
McGuire Sean E et al. JAMA oncology 2021 Feb
(Posted: Feb-12-2021 0PM)
Application of a novel machine learning framework for predicting non-metastatic prostate cancer-specific mortality in men using the Surveillance, Epidemiology, and End Results (SEER) database
C Lee et al, Lancet Digital Health ,February 3, 2021
(Posted: Feb-05-2021 7AM)
Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction.
Conti David V et al. Nature genetics 2021 Jan
(Posted: Jan-06-2021 8AM)
Prostate Cancer Progression and the Epigenome
W Arap et al, NEJM, December 2, 2020
(Posted: Dec-03-2020 7AM)
Prognostic Genomic Biomarkers in Patients With Localized Prostate Cancer: Is Rising Utilization Justified by Evidence?
Lin Daniel W et al. JAMA oncology 2020 Nov
(Posted: Nov-28-2020 0PM)
Regional Adoption of Commercial Gene Expression Testing for Prostate Cancer.
Leapman Michael S et al. JAMA oncology 2020 Nov
(Posted: Nov-28-2020 0PM)
Accelerating precision medicine in metastatic prostate cancer
J Mateo, Nature Cancer, November 17, 2020
(Posted: Nov-20-2020 9AM)
Detection of Pathogenic Variants With Germline Genetic Testing Using Deep Learning vs Standard Methods in Patients With Prostate Cancer and Melanoma.
AlDubayan Saud H et al. JAMA 2020 Nov (19) 1957-1969
(Posted: Nov-18-2020 8AM)
Association of Clonal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-free DNA Testing Interference
K Jensen et al, JAMA Oncology, November 5, 2020
(Posted: Nov-06-2020 7AM)
Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations
S Shmid et al, JAMA Network Open, October 28, 2020
(Posted: Oct-29-2020 11AM)
Racial Differences in Genomic Profiling of Prostate Cancer.
Mahal Brandon A et al. The New England journal of medicine 2020 Sep (11) 1083-1085
(Posted: Sep-10-2020 7AM)
Germline sequencing DNA repair genes in 5,545 men with aggressive and non-aggressive prostate cancer.
Darst Burcu F et al. Journal of the National Cancer Institute 2020 Aug
(Posted: Sep-01-2020 8AM)
Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk Stability.
Cooperberg Matthew R et al. JAMA oncology 2020 Aug e203187
(Posted: Aug-28-2020 8AM)
Clinical deployment of AI for prostate cancer diagnosis
A Janowscyk, Lancet Digital Health, August 1, 2020
(Posted: Jul-31-2020 7AM)
The DNA methylation landscape of advanced prostate cancer
SG Zhao et al, Nature Genetics, July 13, 2020
(Posted: Jul-14-2020 9AM)
Combining liquid biopsies and PET-CT for early cancer detection
SQ Wong et al, Nature Medicine, June 29, 2020
(Posted: Jul-01-2020 8AM)
The effect of sample size on polygenic hazard models for prostate cancer.
Karunamuni Roshan A et al. European journal of human genetics : EJHG 2020 Jun
(Posted: Jun-11-2020 8AM)
Diagnosing hereditary cancer predisposition in men with prostate cancer.
Pritzlaff Mary et al. Genetics in medicine : official journal of the American College of Medical Genetics 2020 May
(Posted: May-23-2020 9AM)
A genomic and epigenomic atlas of prostate cancer in Asian populations
J Li et al, Nature, March 27, 2020
(Posted: Mar-28-2020 8AM)
Risk of Prostate Cancer Associated With Familial and Hereditary Cancer Syndromes.
Beebe-Dimmer Jennifer L et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020 Mar JCO1902808
(Posted: Mar-27-2020 8AM)
Risk stratification of prostate cancer through quantitative assessment of PTEN loss (qPTEN)
JNCI, March 2020
(Posted: Mar-06-2020 8AM)
HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer
JAMA Oncology, February 13, 2020
(Posted: Feb-14-2020 8AM)
Single-Nucleotide Polymorphism–Based Genetic Risk Score and Patient Age at Prostate Cancer Diagnosis
R Na et al, JAMA Network Open, December 27, 2019
(Posted: Dec-27-2019 5PM)
Polygenic risk-tailored screening for prostate cancer: A benefit-harm and cost-effectiveness modelling study.
Callender Tom et al. PLoS medicine 2019 Dec (12) e1002998
(Posted: Dec-21-2019 4PM)
Appraising causal relationships of dietary, nutritional and physical-activity exposures with overall and aggressive prostate cancer: two-sample Mendelian-randomization study based on 79 148 prostate-cancer cases and 61 106 controls
N Kazmi et al, Int J Epi, December 5, 2019
(Posted: Dec-09-2019 8AM)
The BRCA gene is about so much more than breast cancer risk
A Goldman, Well and Good, October 27, 2019
(Posted: Nov-01-2019 10AM)
Ethnic disparities among men with prostate cancer undergoing germline testing.
Kwon Daniel Hyuck-Min et al. Urologic oncology 2019 Oct
(Posted: Oct-23-2019 9AM)
New Precision Medicine Treatment Could Benefit Many Men with Treatment-Resistant Metastatic Prostate Cancer
by Andrea K. Miyahira, Prostate Cancer Foundation, October 1, 2019
(Posted: Oct-11-2019 8AM)
Genome-wide germline correlates of the epigenetic landscape of prostate cancer
KE Houlahan et al, Nature Medicine, October 7, 2019
(Posted: Oct-08-2019 8AM)
Cancer: more genetic BRCA testing for men
M Marabelli et al, Nature, September 17, 2019
(Posted: Sep-20-2019 8AM)
Men, It’s Time for Real Talk about Prostate Health
DM Parker, CDC Blog, August 2019
(Posted: Sep-11-2019 0PM)
More Treatment Options Emerging for Some Men with Metastatic Prostate Cancer
NCI, 2019
(Posted: Sep-03-2019 10AM)
Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors.
Chung Jon H et al. JCO precision oncology 2019 3
(Posted: Jun-26-2019 9AM)
Germline pathogenic variants in 7,636 Japanese patients with prostate cancer and 12,366 controls.
Momozawa Yukihide et al. Journal of the National Cancer Institute 2019 Jun
(Posted: Jun-24-2019 8AM)
Development and validation of a deep learning algorithm for improving Gleason scoring of prostate cancer
K Nagpal et al, NPJ Digital Medicine, June 7, 2019
(Posted: Jun-07-2019 1PM)
NCCN Guidelines Updates: Management of Prostate Cancer.
Mohler James L et al. Journal of the National Comprehensive Cancer Network : JNCCN 2019 May 17(5.5) 583-586
(Posted: May-29-2019 9AM)
Racial Inequality in Prostate Cancer Outcomes—Socioeconomics, Not Biology
CJ Paller et al, JAMA Oncology, May 23, 2019
(Posted: May-27-2019 5PM)
A new era: artificial intelligence and machine learning in prostate cancer.
Goldenberg S Larry et al. Nature reviews. Urology 2019 May
(Posted: May-18-2019 0PM)
Genomic correlates of clinical outcome in advanced prostate cancer.
Abida Wassim et al. Proceedings of the National Academy of Sciences of the United States of America 2019 May
(Posted: May-08-2019 8AM)
A Rich Array of Prostate Cancer Molecular Biomarkers: Opportunities and Challenges.
Kohaar Indu et al. International journal of molecular sciences 2019 Apr 20(8)
(Posted: May-01-2019 9AM)
A 17-Gene Genomic Prostate Score as a Predictor of Adverse Pathology for Men on Active Surveillance.
Kornberg Zachary et al. The Journal of urology 2019 Apr 101097JU0000000000000290
(Posted: May-01-2019 9AM)
Multicenter optimization and validation of a 2-gene mRNA urine test for detection of clinically significant prostate cancer prior to initial prostate biopsy.
Haese Alexander et al. The Journal of urology 2019 Apr 101097JU0000000000000293
(Posted: May-01-2019 9AM)
The Clinical Utility of the Genomic Prostate Score in Men with Very Low to Intermediate Risk Prostate Cancer.
Gaffney Christopher et al. The Journal of urology 2019 Feb 101097JU0000000000000170
(Posted: Apr-03-2019 9AM)
The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis.
Oh Mok et al. The Prostate 2019 Mar
(Posted: Mar-24-2019 9AM)
Defining Prostate Cancer at Favorable Intermediate Risk: the Potential Utility Of Magnetic Resonance Imaging And Genomic Tests.
Falagario Ugo G et al. The Journal of urology 2019 Feb
(Posted: Feb-12-2019 10AM)
Bringing prostate cancer germline genetics into clinical practice.
Das Sanjay et al. The Journal of urology 2019 Feb
(Posted: Feb-12-2019 10AM)
Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines
P. Nicolisi et al, JAMA Oncology, February 8, 2019
(Posted: Feb-08-2019 9AM)
epiCaPture: A Urine DNA Methylation Test for Early Detection of Aggressive Prostate Cancer
E. O'Reilly et al, JCO Precision Oncology, January 2019
(Posted: Jan-22-2019 11AM)
Cost Effectiveness of the Oncotype DX Genomic Prostate Score for Guiding Treatment Decisions in Patients With Early Stage Prostate Cancer.
Chang Eric M et al. Urology 2018 Dec
(Posted: Jan-02-2019 4PM)
Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing.
Giri Veda N et al. The Prostate 2018 Nov
(Posted: Nov-28-2018 8AM)
Germline Genetics of Prostate Cancer: Time to Incorporate Genetics into Early Detection Tools.
Fantus Richard J et al. Clinical chemistry 2018 Nov
(Posted: Nov-28-2018 8AM)
Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer.
Carter H Ballentine et al. European urology 2018 Oct
(Posted: Oct-17-2018 8AM)
Providing clinicians and patients with important information to help guide decisions about prostate cancer screening.
USPSTF, October 8, 2018
(Posted: Oct-09-2018 2PM)
Genetic Counseling Recommended for Advanced Prostate Cancer
M Dalton, Prostate Cancer Advisor, September 17, 2018
(Posted: Sep-18-2018 8AM)
Impact of family history of cancer on risk and mortality of second cancers in patients with prostate cancer.
Chattopadhyay Subhayan et al. Prostate cancer and prostatic diseases 2018 Sep
(Posted: Sep-12-2018 9AM)
Genomic Prostate Score, PI-RADSv2, and Progression in Men with Prostate Cancer on Active Surveillance.
Kornberg Zachary et al. The Journal of urology 2018 Sep
(Posted: Sep-05-2018 9AM)
Liquid biopsy approach in the management of prostate cancer.
Riaz Irbaz Bin et al. Translational research : the journal of laboratory and clinical medicine 2018 May
(Posted: Aug-06-2018 8AM)
Genomic biomarkers in prostate cancer.
Kornberg Zachary et al. Translational andrology and urology 2018 Jun (3) 459-471
(Posted: Aug-06-2018 8AM)
NIH and Prostate Cancer Foundation launch large study on aggressive prostate cancer in African-American men
NCI, July 2018
(Posted: Jul-30-2018 8AM)
Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging.
Grönberg Henrik et al. European urology 2018 Jul
(Posted: Jul-18-2018 9AM)
Differences in inherited risk among relatives of hereditary prostate cancer patients using genetic risk score.
Helfand Brian T et al. The Prostate 2018 Jun
(Posted: Jun-27-2018 10AM)
Prostate cancer spit test is trialled
BBC News, June 11, 2018
(Posted: Jun-11-2018 7PM)
Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci
FR Shcumacher et al, Nature Genetics, June 11, 2018
(Posted: Jun-11-2018 1PM)
Annual Report to the Nation: overall cancer mortality continues to decline, prostate cancer mortality has stabilized
NCI, Press Release, May 22, 2018
(Posted: May-22-2018 10AM)
Prostate-Specific Antigen–Based Screening for Prostate Cancer- Evidence Report and Systematic Review for the US Preventive Services Task Force
JJ Fenton t al, JAMA, May 2018
(Posted: May-14-2018 8AM)
Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement
JAMA, May 8, 2018
(Posted: May-09-2018 8AM)
Disclaimer: Articles listed in Hot Topics of the Day are selected by the CDC Office of Genomics and Precision Public Health to provide current awareness of the scientific literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the Clips, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.
- Page last reviewed:Feb 1, 2023
- Page last updated:Sep 22, 2023
- Content source: